Årsmøte Den Norske Patologforening, Trondheim 7-8 mars 2019:


Årsmøte DNP Trondheim

“Overlege Sveinung Sørbye fra UNN holdt et engasjert innlegg om screening og forebygging av livmorhalskreft hos kvinner yngre enn 40 år og anbefalte rescreening av negative celleprøver med positiv 3-typers HPV mRNA test i denne gruppen”


Az Jan Palfijn, Gent

Zaterdag 16 februari om 9 uur

Lezing: Humaan Papilloma Virus (HPV)

en baarmoederhalskanker (taal : Engels)

Samenwerking tussen de dienst Anatomopathologie van AZ Jan Palfijn Gent en PreTect




HPV Symposium December 2018

Thessaloniki / Athens

The Excelsior / Αιθ. Mezzanine ακολουθεί δείπνο

Crown Plaza Athens City Center



PreTect HPV mRNA clinical data were presented in five free communications!

Because prevention is possible!



May 2018:

Proudly presenting the new concept fighting cervical cancer in Spain:

Self-sampling by XytoTest - HPV Hr-DNA by Abbott and risk stratification by PreTect HPV-Proofer.

An unique combination!

"Mía by XytoTest®, a preventive comprehensive diagnostic system has completed its integration in Spain to prevent cervical cancer.
Our preventive protocol offers a unique sample collection technique ensuring sufficient amount and quality of cervical/vaginal specimens for HPV- testing. These samples will be analyzed targeting DNA to identify HPV-Hr infections using Abbott Laboratories technology.
In addition, to those positive samples for any HPV-Hr infection, a triage process will be implemented by detecting HPV mRNA E6/E7. The triage using the same original sample will risk stratify among the infections and indicate the ones most likely to progress to severe cervical disease or cervical cancer. By identifying the few women at highest risk, follow-up and treatment can be immediately effectuated, hereby preventing cervical cancer. The triage test is the most advanced mRNA method developed, patented by PreTect AS, Norway," said Mel-Mont Medical's COO, Frank Meléndez



Upcoming events

PreTect will be participating in the following events. Don`t hesitate to get in contact; We will be pleased to meet you!

  • Monaco, 4-7 December 2019: “EUROGIN 2019, International multidisciplinary HPV congress”


Recent presentations

  • Sundvolden 24-25 januar 2019: Årsmøte Norsk Forening for Klinisk Cytologi

“Kvalitetssikring av celleprøver med 3-typers HPV mRNA test”

MD.PhD S.W.Sørbye

 “A risk-based approach: co-testing 34,612 women with cytology and a 3-type HPV mRNA test”

MD.PhD S.W.Sørbye

Primary cervical screening with a 5-type HPV E6/E7 mRNA test: Results of 10 years follow-up

Prof. MD. F.E.Skjeldestad

“3-type HPV mRNA test in detection of CIN2+ in young women with normal cytology “

MD. K. Al-Shibli

“Is co-testing with a 3-type HPV MRNA test a better strategy for women 21-29 years than cytology only? “

MD.PhD S.W.Sørbye

“The added value of rescreening cytology normal samples with positive HPV mRNA test for the detection of CIN2+ in primary screening”

Prof. MD. F.E.Skjeldestad

  • Rome, 12-13 April 2018: "13th Workshop on Lower Genital Tract Pathology"

"Primary cervical screening with a 5-type HPV E6/E7 mRNA test: Results of 10 years follow-up"

MD.PhD S.W.Sørbye


       "HPV test in triage of ASC-US/LSIL- the risk of CIN3+ in 5-type HPV E6/E7 mRNA negative women"

MD.PhD S.W.Sørbye


       "Cytology and 3-type HPV E6/E7 mRNA co-testing in women 25-33 years"

MD.PhD S.W.Sørbye


       "Detection of CIN2+ in women with normal cytology-

The added value of a 3-type HPV E6/E7 mRNA test"

MD.PhD S.W.Sørbye


  • Årsmøte Norsk Forening for Klinisk Cytologi, Sundvolden 25-26 januar 2018

"Rescreening av normale cytologiprøver med positiv HPV mRNA test"

       MD. C.J. Nybø


  • EUROGIN 2017, Amsterdam 08-11 October 2017

"5-type HPV mRNA negative women in triage of ASC-US/LSIL may return to screening at 3-year interval - an historical prospective cohort study"

Prof. MD. F.E.Skjeldestad


"Detection of CIN2+ in women with normal Cytology using a 3 -type HPV mRNA test"

MD.PhD S.W.Sørbye